-transparent.png){kind=logo}
The effect of furosemide on urinary kallikrein excretion was studied in 10 patients with essential hypertension and 9 normal volunteer subjects. After intravenous administration of furosemide and 2 hours of upright posture, urine volume (UV), urinary sodium (UNaV) and potassium (UKV) excretion, plasma renin activity (PRA), plasma aldosterone concentration (PAC) and urinary kallikrein markedly increased. However, the augmentation of urinary kallikrein in patients with essential hypertension (1.50 +/- 0.19 EU/2 hr) was less remarkable than that in normal subjects (2.33 +/- 0.24 EU/2 hr), although the same degrees of response were observed in PRA and PAC. The increments of UV, UNaV and UKV in patients with essential hypertension were also significantly lower than in normal subjects. Significant positive relations were found between urinary kallikrein and UV or UNaV in both hypertensive and normotensive groups, but there was no such correlation before fursemide administration. It is likely that diuresis and natriuresis induced by furosemide are somehow associated with an increase in urinary kallikrein excretion. Blunted response of urinary kallikrein in essential hypertension may suggest an abnormality in the renal kallikrein-kinin system in this disease.
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
December 1973,
Agents and actions,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
January 1989,
Advances in experimental medicine and biology,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
September 1977,
Prostaglandins,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
January 1979,
Minerva nefrologica,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
May 1981,
The Journal of clinical endocrinology and metabolism,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
February 1980,
The Journal of clinical investigation,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
October 1985,
Archives of disease in childhood,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
September 1981,
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
February 1984,
British journal of pharmacology,
M Seino, and
K Abe, and
N Irokawa, and
T Ito, and
M Yasujima, and
Y Sakurai, and
S Chiba, and
K Saito, and
K Ritz, and
T Kusaka, and
S Miyazaki, and
K Yoshinaga
August 1992,
Journal of hypertension,
